Surgery alone or plus chemotherapy for early lung cancer
Part of Cancer clinical trials.
This trial studies whether adding chemotherapy after surgery helps people with early-stage lung adenocarcinoma that has a micropapillary pattern. It’s testing whether chemotherapy given after complete tumor removal can improve outcomes compared with surgery alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer was completely removed by surgery (early Stage I) and fully resected
- Your pathology report shows lung adenocarcinoma with a micropapillary component of at least 20%
- You can start the study randomization within 4 weeks after your surgery
- You have not had chemotherapy or radiation for non-small cell lung cancer before joining
- You do not have cancer spread to distant parts of the body (no metastases)
- Your general condition is good (performance status 0 or 1) and key blood tests and liver numbers are within limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the immunotherapy drug sugemalimab to standard chemotherapy before and after surgery can help people with stage II-IIIA non-small cell lung cancer. It aims to see if this combination reduces the chance of cancer coming back.
This trial tests a combination of immunotherapy (adebrelimab), a targeted therapy (apatinib), and chemotherapy given before surgery for people with limited-stage small cell lung cancer. The goal is to see if this treatment shrinks the tumor enough to make surgery more effective and to study markers that might predict response.
This trial tests giving chemotherapy followed by the immunotherapy drug sintilimab before surgery for people with EGFR-mutant, early-stage non-small cell lung cancer. It aims to see if this combination reduces the tumor and improves outcomes before surgical removal.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
Hear when a new Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.